|
|
 |
|
Viewing report
|
|
|
|
United States Pharmaceuticals & Healthcare Report Q1 2008
Business Monitor International, Feb 2008, Pages: 113
Executive Summary 5
US Pharmaceuticals And Healthcare Industry SWOT 6
Pharmaceutical Business Environment Rating 7
Pharmaceutical Ratings - Revised Methodology 7
Ratings Overview 7
Table: Pharmaceutical Business Environment Indicators 8
Weighting 9
Table: Weighting Of Components 9
United States Business Enviroment Ranking 10
Table: Americas Pharmaceutical Business Environment Rankings 10
Limits To Potential Returns 10
United States - Market Summary 12
Regulatory Regime13
Intellectual Property Developments 17
Pricing And Reimbursement Issues 19
Industry Developments23
Healthcare sector 23
Universal Healthcare 25
Table: US Health Insurance Key States, 2005 26
Part D 27
Democrats Controlling Congress 30
Biotechnology Sector 31
Table: Biotechnology Medicines Under Development, 2006 32
Table: Top 10 2006 Biotech IPOs 33
Statins 34
Advertising Sector 35
Product Approvals 37
Mergers And Acquisitions 41
Marketing Sector 43
Reseach And Development Sector 47
Generics Sector 52
Wal-Mart Enters The Fray 56
Authorised Generics 57
Biogenerics 59
Canadian Imports 62
Pharmacy Sector 63
Manufacturing Sector 63
Industry Forecast Scenario 65
Overall Market Forecast 65
Table: US Pharmaceuticals And Healthcare Sector - Historical Data And Forecasts 66
Key Growth Factors - Industry 67
Key Growth Factors - Macroeconomic 68
Table: United States - Macroeconomic Forecasts 70
Prescription Market Forecast 71
Table: US Pharmaceuticals And Healthcare Sector - Historical Data And Forecasts (US$mn unless othewise stated) 72
OTC Market Forecast 73
Table: OTC Market Indicators (US$mn unless otherwise stated) 74
Generics Market Forecast 75
Table: Generics And Patented Market Indicators 76
Export/Import Forecasts 77
Table: US Pharmaceuticals And Healthcare Sector (US$mn) 78
Other Healthcare Data 79
Table: US Pharmaceuticals And Healthcare Sector 79
Table: US Pharmaceuticals And Healthcare Sector 79
Competitive Landscape80
Overview 80
Market Data 81
Table: Leading 10 Therapeutic Classes by US Sales, 2006 81
Table: Leading 10 Products By US Sales, 2006 81
Table: Leading 10 Corporations By US Sales, 2005 82
Table: Leading 10 Corporations By Total US Dispensed Prescriptions, 2006 83
Table: Chanel Distribution By US Dispensed Prescription Chanel, 2006 83
Table: Channel Distribution By US Sales, 2006 84
Table: Leading 10 Products By Total US Dispensed Prescriptions, 2006 84
Table: HMG-COA Reductase Inhibitors (statins) - Total US Sales (US$’000) 85
Table: Proton Pump Inhibitors - Total US Sales (US$’000) 85
Table: Antidepressants (includes SSRI, SNRI and newer generation) - Total US Sales (US$’000) 85
Table: Antiarthitics, COX-2 Inhibitors - Total US Sales (US$’000) 86
Table: Sexual Function Disorder - Total US Sales (US$’000) 86
Company Profiles87
Pfizer 87
GlaxoSmithKline (GSK) 92
Novartis 94
Merck & Co 96
Eli Lilly 100
Bristol-Myers Squibb (BMS) 103
Amgen 107
Genentech 109
BMI Forecast Modellin111
How We Generate Our Industry Forecasts 111
Pharmaceutical Industry 112
Sources 112
Customers who bought this item also bought
US Pharmaceuticals and Healthcare Report Q3 2007
United States Pharmaceuticals and Healthcare Report Q2 2008
United States Pharmaceuticals and Healthcare Report Q4 2008
United States Pharmaceuticals and Healthcare Report Q2 2009
United States Pharmaceuticals and Healthcare Report Q3 2008
United States Pharmaceuticals and Healthcare Report Q3 2009
United States Pharmaceuticals and Healthcare Report Q4 2009
Lithuania Pharmaceuticals & Healthcare Report Q4 2006
Pharmaceuticals - Global Outlook
United Kingdom Pharmaceuticals and Healthcare Report Q2 2008
United Kingdom Pharmaceuticals and Healthcare Report Q4 2009
Romania Pharmaceuticals and Healthcare Report Q4 2009
|
|
|
|
